ADVERSE REACTIONS SECTION.


6 ADVERSE REACTIONS. Common adverse reactions (>=30%) observed in combination therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, mucositis, neutropenia, leukopenia (including lymphocytopenia), anemia, thrombocytopenia, asthenia, pain, fever, infection, abnormal bilirubin, alopecia. (6.1)Common adverse reactions (>=30%) observed in single agent therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, neutropenia, leukopenia (including lymphocytopenia), anemia, asthenia, fever, body weight decreasing, alopecia. (6.1)To report SUSPECTED ADVERSE REACTIONS, contact Areva at 1-855-853-4760 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.Common adverse reactions (>=30%) observed in combination therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, mucositis, neutropenia, leukopenia (including lymphocytopenia), anemia, thrombocytopenia, asthenia, pain, fever, infection, abnormal bilirubin, and alopecia.Common adverse reactions (>=30%) observed in single agent therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, neutropenia, leukopenia (including lymphocytopenia), anemia, asthenia, fever, body weight decreasing, and alopecia.First-Line Combination TherapyA total of 955 patients with metastatic colorectal cancer received the recommended regimens of irinotecan in combination with 5-FU/LV, 5-FU/LV alone, or irinotecan alone. In the two phase studies, 370 patients received irinotecan in combination with 5-FU/LV, 362 patients received 5-FU/LV alone, and 223 patients received irinotecan alone [see Dosage and Administration (2)]. In Study 1, 49 (7.3%) patients died within 30 days of last study treatment: 21 (9.3%) received irinotecan in combination with 5-FU/LV, 15 (6.8%) received 5-FU/LV alone, and 13 (5.8%) received irinotecan alone. Deaths potentially related to treatment occurred in (0.9%) patients who received irinotecan in combination with 5-FU/LV (2 neutropenic fever/sepsis), (1.4%) patients who received 5-FU/LV alone (1 neutropenic fever/sepsis, CNS bleeding during thrombocytopenia, unknown) and (0.9%) patients who received irinotecan alone (2 neutropenic fever). Deaths from any cause within 60 days of first study treatment were reported for 15 (6.7%) patients who received irinotecan in combination with 5-FU/LV, 16 (7.3%) patients who received 5-FU/LV alone, and 15 (6.7%) patients who received irinotecan alone. Discontinuations due to adverse events were reported for 17 (7.6%) patients who received irinotecan in combination with 5FU/LV, 14 (6.4%) patients who received 5-FU/LV alone, and 26 (11.7%) patients who received irinotecan alone.In Study 2, 10 (3.5%) patients died within 30 days of last study treatment: (4.1%) received irinotecan in combination with 5-FU/LV and (2.8%) received 5-FU/LV alone. There was one potentially treatment-related death, which occurred in patient who received irinotecan in combination with 5-FU/LV (0.7%, neutropenic sepsis). Deaths from any cause within 60 days of first study treatment were reported for (2.1%) patients who received irinotecan in combination with 5-FU/LV and (1.4%) patients who received 5-FU/LV alone. Discontinuations due to adverse events were reported for (6.2%) patients who received irinotecan in combination with 5FU/LV and (0.7%) patient who received 5-FU/LV alone.The most clinically significant adverse events for patients receiving irinotecan-based therapy were diarrhea, nausea, vomiting, neutropenia, and alopecia. The most clinically significant adverse events for patients receiving 5-FU/LV therapy were diarrhea, neutropenia, neutropenic fever, and mucositis. In Study 1, grade neutropenia, neutropenic fever (defined as grade fever and grade neutropenia), and mucositis were observed less often with weekly irinotecan/5-FU/LV than with monthly administration of 5-FU/LV.Tables and list the clinically relevant adverse events reported in Studies and 2, respectively.Table 5. Study 1: Percent (%) of Patients Experiencing Clinically Relevant Adverse Events in Combination Therapies Adverse EventStudy 1Irinotecan Bolus 5-FU/LVweekly 4 every weeks N=225Bolus 5-FU/LVdaily 5 every weeks N=219Irinotecanweekly 4 every weeks N=223Grade 1-4Grade3&4Grade 1-4Grade 3&4Grade 1-4Grade 3&4TOTAL Adverse Events10053.310045.799.645.7GASTROINTESTINALDiarrheaLate84.922.769.413.283.031.0grade 3---15.1---5.9---18.4grade 4---7.6---7.3---12.6Early45.84.931.51.443.06.7Nausea79.115.667.68.281.616.1Abdominal pain63.114.650.211.567.713.0Vomiting60.49.746.14.162.812.1Anorexia34.25.842.03.743.97.2Constipation41.33.131.51.832.30.4Mucositis32.42.276.316.929.62.2HEMATOLOGICNeutropenia96.953.898.666.796.431.4grade 3---29.8---23.7---19.3grade 4---24.0---42.5---12.1Leukopenia96.937.898.623.396.421.5Anemia96.98.498.65.596.94.5Neutropenic fever---7.1---14.6---5.8Thrombocytopenia96.02.698.62.796.01.7Neutropenic infection---1.8---0---2.2BODY AS WHOLEAsthenia70.219.564.411.969.113.9Pain30.73.126.93.622.92.2Fever42.21.732.43.643.50.4Infection22.2016.01.413.90.4METABOLIC NUTRITIONALBilirubin87.67.192.28.283.97.2DERMATOLOGICExfoliative dermatitis0.903.20.500Rash19.1026.50.914.30.4Alopecia 43.1---26.5---46.1---RESPIRATORYDyspnea27.66.316.00.522.02.2Cough26.71.318.3020.20.4Pneumonia6.22.71.41.03.61.3NEUROLOGICDizziness23.11.316.4021.11.8Somnolence12.41.84.61.89.41.3Confusion7.11.84.102.70CARDIOVASCULARVasodilatation9.30.95.009.00Hypotension5.81.32.30.55.81.7Thromboembolic events 9.3---11.4---5.4---a Severity of adverse events based on NCI CTC (version 1.0) Complete hair loss Grade c Includes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder. Table 6. Study 2: Percent (%) of Patients Experiencing Clinically Relevant Adverse Events in Combination Therapies Adverse EventStudy 2Irinotecan 5-FU/LV infusional days 1&2 every weeks N=1455-FU/LV infusion days 1&2 every weeks N=143Grades 1-4Grades 3&4Grades 1-4Grades 3&4Total Adverse Events10072.410039.2GASTROINTESTINALDiarrhealate72.414.444.86.3grade 3--10.3---4.2grade 4---4.1---2.1Cholinergic syndrome 28.31.40.70Nausea66.92.155.23.5Abdominal pain17.22.116.80.7Vomiting44.83.532.22.8Anorexia35.22.118.90.7Constipation30.30.725.21.4Mucositis40.04.128.72.8HEMATOLOGICNeutropenia82.546.247.913.4grade 3---36.4---12.7grade 4---9.8---0.7Leukopenia81.317.442.03.5Anemia97.22.190.92.1Neutropenic fever---3.4---0.7Thrombocytopenia32.6032.20Neutropenic infection---2.1---0BODY AS WHOLEAsthenia57.99.048.34.2Pain64.19.761.58.4Fever22.10.725.90.7Infection35.97.633.63.5METABOLIC AND NUTRITIONALBilirubin19.13.535.910.6DERMATOLOGICHand and foot syndrome10.30.712.60.7Cutaneous signs17.20.720.30Alopecia 56.6---16.8---RESPIRATORYDyspnea9.71.44.90CARDIOVASCULARHypotension3.41.40.70Thromboembolic events 11.7---5.6---a Severity of adverse events based on NCI CTC (version 1.0) Includes rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, abdominal cramping or diarrhea (occurring during or shortly after infusion of irinotecan) Complete hair loss Grade d Includes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder. Second-Line Single-Agent TherapyWeekly Dosage ScheduleIn three clinical studies evaluating the weekly dosage schedule, 304 patients with metastatic carcinoma of the colon or rectum that had recurred or progressed following 5-FU-based therapy were treated with irinotecan hydrochloride. Seventeen of the patients died within 30 days of the administration of irinotecan hydrochloride; in five cases (1.6%, 5/304), the deaths were potentially drug-related. One of the patients died of neutropenic sepsis without fever. Neutropenic fever occurred in nine (3.0%) other patients; these patients recovered with supportive care.One hundred nineteen (39.1%) of the 304 patients were hospitalized because of adverse events; 81 (26.6%) patients were hospitalized for events judged to be related to administration of irinotecan hydrochloride. The primary reasons for drug-related hospitalization were diarrhea, with or without nausea and/or vomiting (18.4%); neutropenia/leukopenia, with or without diarrhea and/or fever (8.2%); and nausea and/or vomiting (4.9%).The first dose of at least one cycle of irinotecan hydrochloride was reduced for 67% of patients who began the studies at the 125-mg/m starting dose. Within-cycle dose reductions were required for 32% of the cycles initiated at the 125-mg/m dose level. The most common reasons for dose reduction were late diarrhea, neutropenia, and leukopenia. Thirteen (4.3%) patients discontinued treatment with irinotecan hydrochloride because of adverse events. The adverse events in Table are based on the experience of the 304 patients enrolled in the three studies described in Clinical Studies (14.1). Table 7. Adverse Events Occurring in >10% of 304 Previously Treated Patients with Metastatic Carcinoma of the Colon or RectumaBody System Event% of Patients ReportingNCI Grades 1-4NCI Grades & 4GASTROINTESTINALDiarrhea (late)b7-9 stools/day (grade 3)>=10 stools/day (grade 4) NauseaVomitingAnorexiaDiarrhea (early)cConstipationFlatulenceStomatitisDyspepsia88--866755513012121031(16)(14)1712682010HEMATOLOGICLeukopeniaAnemiaNeutropenia500 to <1000/mm3 (grade 3)<500/mm3 (grade 4)636054--28726(15)(12)BODY AS WHOLEAstheniaAbdominal cramping/painFeverPainHeadacheBack painChillsMinor infection EdemaAbdominal enlargement76574524171414141010121612120010METABOLIC NUTRITIONAL Body weightDehydration Alkaline phosphatase SGOT301513101441DERMATOLOGICAlopeciaSweatingRash601613NA 01RESPIRATORYDyspnea CoughingRhinitis221716400NEUROLOGICInsomniaDizziness191500CARDIOVASCULARVasodilation (flushing)110a Severity of adverse events based on NCI CTC (version 1.0) Occurring >24 hours after administration of irinotecan hydrochloride Occurring <=24 hours after administration of irinotecan hydrochloride Primarily upper respiratory infections Not applicable; complete hair loss NCI grade Once-Every-3-Week Dosage ScheduleA total of 535 patients with metastatic colorectal cancer whose disease had recurred or progressed following prior 5-FU therapy participated in the two phase studies: 316 received irinotecan, 129 received 5-FU, and 90 received best supportive care. Eleven (3.5%) patients treated with irinotecan died within 30 days of treatment. In three cases (1%, 3/316), the deaths were potentially related to irinotecan treatment and were attributed to neutropenic infection, grade diarrhea, and asthenia, respectively. One (0.8%, 1/129) patient treated with 5-FU died within 30 days of treatment; this death was attributed to grade diarrhea.Hospitalizations due to serious adverse events occurred at least once in 60% (188/316) of patients who received irinotecan, 63% (57/90) who received best supportive care, and 39% (50/129) who received 5-FU-based therapy. Eight percent of patients treated with irinotecan and 7% treated with 5-FU-based therapy discontinued treatment due to adverse events.Of the 316 patients treated with irinotecan, the most clinically significant adverse events (all grades, 1-4) were diarrhea (84%), alopecia (72%), nausea (70%), vomiting (62%), cholinergic symptoms (47%), and neutropenia (30%). Table lists the grade and adverse events reported in the patients enrolled to all treatment arms of the two studies described in Clinical Studies (14.1).Table 8: Percent Of Patients Experiencing Grade & Adverse Events In Comparative Studies Of Once-Every-3-Week Irinotecan Therapy Adverse EventStudy 1Study 2IrinotecanN=189BSC N=90IrinotecanN=1275-FUN=129TOTAL Grade 3/4Adverse Events79676954GASTROINTESTINALDiarrheaVomitingNauseaAbdominal painConstipationAnorexiaMucositis22141414105268316871221411986211548645HEMATOLOGICLeukopenia/Neutropenia AnemiaHemorrhageThrombocytopeniaInfectionwithout grade 3/4neutropeniawith grade 3/4 neutropeniaFeverwithout grade 3/4neutropeniawith grade 3/4 neutropenia2275181220630301014614122423324002BODY AS WHOLEPainAsthenia1915221917131312METABOLIC AND NUTRITIONALHepatic 9796DERMATOLOGICHand and foot syndromeCutaneous signs 02000153RESPIRATORY e10857NEUROLOGIC 121394CARDIOVASCULARg9342OTHER 32281214a Severity of adverse events based on NCI CTC (version 1.0) BSC best supportive care Hepatic includes events such as ascites and jaundice Cutaneous signs include events such as rash Respiratory includes events such as dyspnea and cough Neurologic includes events such as somnolence Cardiovascular includes events such as dysrhythmias, ischemia, and mechanical cardiac dysfunction Other includes events such as accidental injury, hepatomegaly, syncope, vertigo, and weight loss The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as irinotecan hydrochloride than when these drugs were given on separate days (1.3%, 1/80 patients). The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as premedication for other chemotherapies.. 6.2 Postmarketing Experience. The following adverse reactions have been identified during post approval use of irinotecan hydrochloride. Because these reactions are reported voluntarily from population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure.Myocardial ischemic events have been observed following irinotecan hydrochloride therapy. Thromboembolic events have been observed in patients receiving irinotecan hydrochloride.Symptomatic pancreatitis, asymptomatic pancreatic enzyme elevation have been reported. Increases in serum levels of transaminases (i.e., AST and ALT) in the absence of progressive liver metastasis have been observed.Hyponatremia, mostly with diarrhea and vomiting, has been reported.Transient dysarthria has been reported in patients treated with irinotecan hydrochloride; in some cases, the event was attributed to the cholinergic syndrome observed during or shortly after infusion of irinotecan.Interaction between irinotecan hydrochloride and neuromuscular blocking agents cannot be ruled out. Irinotecan has anticholinesterase activity, which may prolong the neuromuscular blocking effects of suxamethonium and the neuromuscular blockade of non-depolarizing drugs may be antagonized.Infections: fungal and viral infections have been reported.

BOXED WARNING SECTION.


WARNING: DIARRHEA and MYELOSUPPRESSIONEarly and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea can be life threatening and should be treated promptly with loperamide. Monitor patients with diarrhea and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop ileus, fever, or severe neutropenia. Interrupt irinotecan hydrochloride injection and reduce subsequent doses if severe diarrhea occurs [see Dosage and Administration (2.2) and Warnings and Precautions (5.1)]. Severe myelosuppression may occur see Warnings and Precautions (5.2)] Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea can be life threatening and should be treated promptly with loperamide. Monitor patients with diarrhea and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop ileus, fever, or severe neutropenia. Interrupt irinotecan hydrochloride injection and reduce subsequent doses if severe diarrhea occurs [see Dosage and Administration (2.2) and Warnings and Precautions (5.1)]. Severe myelosuppression may occur see Warnings and Precautions (5.2)] WARNING: DIARRHEA and MYELOSUPPRESSIONSee full prescribing information for complete boxed warning.Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea can be life threatening and should be treated promptly with loperamide. Monitor patients with diarrhea and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop ileus, fever, or severe neutropenia. Interrupt irinotecan hydrochloride and reduce subsequent doses if severe diarrhea occurs. (2.2, 5.1)Severe myelosuppression may occur. (5.2). Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea can be life threatening and should be treated promptly with loperamide. Monitor patients with diarrhea and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop ileus, fever, or severe neutropenia. Interrupt irinotecan hydrochloride and reduce subsequent doses if severe diarrhea occurs. (2.2, 5.1). Severe myelosuppression may occur. (5.2).

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.


13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term carcinogenicity studies with irinotecan were not conducted. Rats were, however, administered intravenous doses of mg/kg or 25 mg/kg irinotecan once per week for 13 weeks (in separate studies, the 25 mg/kg dose produced an irinotecan max and AUC that were about 7.0 times and 1.3 times the respective values in patients administered 125 mg/m weekly) and were then allowed to recover for 91 weeks. Under these conditions, there was significant linear trend with dose for the incidence of combined uterine horn endometrial stromal polyps and endometrial stromal sarcomas. Irinotecan was clastogenic both in vitro (chromosome aberrations in Chinese hamster ovary cells) and in vivo (micronucleus test in mice). Neither irinotecan nor its active metabolite SN-38 was mutagenic in the in vitro Ames assay. No significant adverse effects on fertility and general reproductive performance were observed after intravenous administration of irinotecan in doses of up to mg/kg/day to rats and rabbits; however, atrophy of male reproductive organs was observed after multiple daily irinotecan doses both in rodents at 20 mg/kg and in dogs at 0.4 mg/kg. In separate studies in rodents, this dose produced an irinotecan max and AUC about and times, respectively, of the corresponding values in patients administered 125 mg/m weekly. In dogs this dose produced an irinotecan max and AUC about one-half and 1/15th, respectively, of the corresponding values in patients administered 125 mg/m weekly.

CLINICAL PHARMACOLOGY SECTION.


12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Irinotecan is derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.. 12.2 Pharmacodynamics. Irinotecan serves as water-soluble precursor of the lipophilic metabolite SN-38. SN-38 is formed from irinotecan by carboxylesterase-mediated cleavage of the carbamate bond between the camptothecin moiety and the dipiperidino side chain. SN-38 is approximately 1000 times as potent as irinotecan as an inhibitor of topoisomerase purified from human and rodent tumor cell lines. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold; however, the plasma area under the concentration versus time curve (AUC) values for SN-38 are 2% to 8% of irinotecan and SN-38 is 95% bound to plasma proteins compared to approximately 50% bound to plasma proteins for irinotecan [see Clinical Pharmacology (12.3)]. The precise contribution of SN-38 to the activity of irinotecan hydrochloride is thus unknown. Both irinotecan and SN-38 exist in an active lactone form and an inactive hydroxy acid anion form. pH-dependent equilibrium exists between the two forms such that an acid pH promotes the formation of the lactone, while more basic pH favors the hydroxy acid anion form. Administration of irinotecan has resulted in antitumor activity in mice bearing cancers of rodent origin and in human carcinoma xenografts of various histological types.. 12.3 Pharmacokinetics. After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in multiexponential manner, with mean terminal elimination half-life of about to 12 hours. The mean terminal elimination half-life of the active metabolite SN-38 is about 10 to 20 hours. The half-lives of the lactone (active) forms of irinotecan and SN-38 are similar to those of total irinotecan and SN-38, as the lactone and hydroxy acid forms are in equilibrium.Over the recommended dose range of 50 to 350 mg/m 2, the AUC of irinotecan increases linearly with dose; the AUC of SN-38 increases less than proportionally with dose. Maximum concentrations of the active metabolite SN-38 are generally seen within hour following the end of 90-minute infusion of irinotecan. Pharmacokinetic parameters for irinotecan and SN-38 following 90-minute infusion of irinotecan at dose levels of 125 and 340 mg/m determined in two clinical studies in patients with solid tumors are summarized in Table 9: Table 9. Summary of Mean (+-Standard Deviation) Irinotecan and SN-38 Pharmacokinetic Parameters in Patients with Solid TumorsDose(mg/m 2) IrinotecanSN-38C max (ng/mL)AUC 0-24 (ng.h/mL)t 1/2 (h)V (L/m 2) CL(L/h/m 2) max (ng/mL)AUC 0-24 (ng.h/mL)t 1/2 (h)125(N=64)1,660+-79710,200+-3,2705.8 +-0.7110+-48.513.3+-6.0126.3+-11.9229+-10810.4 +-3.1340(N=6)3,392+-87420,604+-6,02711.7 +-1.0234+-69.613.9+-4.056.0+-28.2474+-24521.0 +-4.3C max Maximum plasma concentration AUC 0-24 Area under the plasma concentration-time curve from time to 24 hours after the end of the 90-minute infusiont 1/2 Terminal elimination half-life z Volume of distribution of terminal elimination phase CL Total systemic clearancea Plasma specimens collected for 24 hours following the end of the 90-minute infusion Plasma specimens collected for 48 hours following the end of the 90-minute infusion. Because of the longer collection period, these values provide more accurate reflection of the terminal elimination half-lives of irinotecan and SN-38. DistributionIrinotecan exhibits moderate plasma protein binding (30% to 68% bound). SN-38 is highly bound to human plasma proteins (approximately 95% bound). The plasma protein to which irinotecan and SN-38 predominantly binds is albumin.MetabolismIrinotecan is subject to extensive metabolic conversion by various enzyme systems, including esterases to form the active metabolite SN-38, and UGT1A1 mediating glucuronidation of SN-38 to form the inactive glucuronide metabolite SN-38G. Irinotecan can also undergo CYP3A4- mediated oxidative metabolism to several inactive oxidation products, one of which can be hydrolyzed by carboxylesterase to release SN-38. In vitro studies indicate that irinotecan, SN-38 and another metabolite aminopentane carboxylic acid (APC), do not inhibit cytochrome P-450 isozymes. UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A128 polymorphism. Approximately 10% of the North American population is homozygous for the UGT1A128 allele (also referred to as UGT1A1 7/7 genotype). In prospective study, in which irinotecan was administered as single-agent (350 mg/m 2) on once-every-3-week schedule, patients with the UGT1A1 7/7 genotype had higher exposure to SN-38 than patients with the wild-type UGT1A1 allele (UGT1A1 6/6 genotype) [see Warnings and Precautions (5.3) and Dosage and Administration (2.3)]. SN-38 glucuronide had 1/50 to 1/100 the activity of SN-38 in cytotoxicity assays using two cell lines in vitro. ExcretionThe disposition of irinotecan has not been fully elucidated in humans. The urinary excretion of irinotecan is 11% to 20%; SN-38, <1%; and SN-38 glucuronide, 3%. The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over period of 48 hours following administration of irinotecan in two patients ranged from approximately 25% (100 mg/m 2) to 50% (300 mg/m 2). Effect of AgeThe pharmacokinetics of irinotecan administered using the weekly schedule was evaluated in study of 183 patients that was prospectively designed to investigate the effect of age on irinotecan toxicity. Results from this trial indicate that there are no differences in the pharmacokinetics of irinotecan, SN-38, and SN-38 glucuronide in patients <65 years of age compared with patients >=65 years of age. In study of 162 patients that was not prospectively designed to investigate the effect of age, small (less than 18%) but statistically significant differences in dose-normalized irinotecan pharmacokinetic parameters in patients <65 years of age compared to patients >=65 years of age were observed. Although dose-normalized AUC 0-24 for SN-38 in patients >=65 years of age was 11% higher than in patients <65 years of age, this difference was not statistically significant. No change in the starting dose is recommended for geriatric patients receiving the weekly dosage schedule of irinotecan [see Dosage and Administration (2)]. Effect of GenderThe pharmacokinetics of irinotecan do not appear to be influenced by gender.Effect of RaceThe influence of race on the pharmacokinetics of irinotecan has not been evaluated.Effect of Hepatic ImpairmentIrinotecan clearance is diminished in patients with hepatic impairment while exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function. The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations. However, the tolerability of irinotecan in patients with hepatic dysfunction (bilirubin greater than mg/dl) has not been assessed sufficiently, and no recommendations for dosing can be made [see Dosage and Administration (2.1), Warnings and Precautions (5.10) and Use in Specific Populations (8.7)]. Effect of Renal ImpairmentThe influence of renal impairment on the pharmacokinetics of irinotecan has not been evaluated. Therefore, caution should be undertaken in patients with impaired renal function. Irinotecan hydrochloride is not recommended for use in patients on dialysis [see Use in Specific Populations (8.6)]. Drug InteractionsDexamethasone, moderate CYP3A4 inducer, does not appear to alter the pharmacokinetics of irinotecan.

CLINICAL STUDIES SECTION.


6.1 Clinical Studies Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.Common adverse reactions (>=30%) observed in combination therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, mucositis, neutropenia, leukopenia (including lymphocytopenia), anemia, thrombocytopenia, asthenia, pain, fever, infection, abnormal bilirubin, and alopecia.Common adverse reactions (>=30%) observed in single agent therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, neutropenia, leukopenia (including lymphocytopenia), anemia, asthenia, fever, body weight decreasing, and alopecia.First-Line Combination TherapyA total of 955 patients with metastatic colorectal cancer received the recommended regimens of irinotecan in combination with 5-FU/LV, 5-FU/LV alone, or irinotecan alone. In the two phase studies, 370 patients received irinotecan in combination with 5-FU/LV, 362 patients received 5-FU/LV alone, and 223 patients received irinotecan alone [see Dosage and Administration (2)]. In Study 1, 49 (7.3%) patients died within 30 days of last study treatment: 21 (9.3%) received irinotecan in combination with 5-FU/LV, 15 (6.8%) received 5-FU/LV alone, and 13 (5.8%) received irinotecan alone. Deaths potentially related to treatment occurred in (0.9%) patients who received irinotecan in combination with 5-FU/LV (2 neutropenic fever/sepsis), (1.4%) patients who received 5-FU/LV alone (1 neutropenic fever/sepsis, CNS bleeding during thrombocytopenia, unknown) and (0.9%) patients who received irinotecan alone (2 neutropenic fever). Deaths from any cause within 60 days of first study treatment were reported for 15 (6.7%) patients who received irinotecan in combination with 5-FU/LV, 16 (7.3%) patients who received 5-FU/LV alone, and 15 (6.7%) patients who received irinotecan alone. Discontinuations due to adverse events were reported for 17 (7.6%) patients who received irinotecan in combination with 5FU/LV, 14 (6.4%) patients who received 5-FU/LV alone, and 26 (11.7%) patients who received irinotecan alone.In Study 2, 10 (3.5%) patients died within 30 days of last study treatment: (4.1%) received irinotecan in combination with 5-FU/LV and (2.8%) received 5-FU/LV alone. There was one potentially treatment-related death, which occurred in patient who received irinotecan in combination with 5-FU/LV (0.7%, neutropenic sepsis). Deaths from any cause within 60 days of first study treatment were reported for (2.1%) patients who received irinotecan in combination with 5-FU/LV and (1.4%) patients who received 5-FU/LV alone. Discontinuations due to adverse events were reported for (6.2%) patients who received irinotecan in combination with 5FU/LV and (0.7%) patient who received 5-FU/LV alone.The most clinically significant adverse events for patients receiving irinotecan-based therapy were diarrhea, nausea, vomiting, neutropenia, and alopecia. The most clinically significant adverse events for patients receiving 5-FU/LV therapy were diarrhea, neutropenia, neutropenic fever, and mucositis. In Study 1, grade neutropenia, neutropenic fever (defined as grade fever and grade neutropenia), and mucositis were observed less often with weekly irinotecan/5-FU/LV than with monthly administration of 5-FU/LV.Tables and list the clinically relevant adverse events reported in Studies and 2, respectively.Table 5. Study 1: Percent (%) of Patients Experiencing Clinically Relevant Adverse Events in Combination Therapies Adverse EventStudy 1Irinotecan Bolus 5-FU/LVweekly 4 every weeks N=225Bolus 5-FU/LVdaily 5 every weeks N=219Irinotecanweekly 4 every weeks N=223Grade 1-4Grade3&4Grade 1-4Grade 3&4Grade 1-4Grade 3&4TOTAL Adverse Events10053.310045.799.645.7GASTROINTESTINALDiarrheaLate84.922.769.413.283.031.0grade 3---15.1---5.9---18.4grade 4---7.6---7.3---12.6Early45.84.931.51.443.06.7Nausea79.115.667.68.281.616.1Abdominal pain63.114.650.211.567.713.0Vomiting60.49.746.14.162.812.1Anorexia34.25.842.03.743.97.2Constipation41.33.131.51.832.30.4Mucositis32.42.276.316.929.62.2HEMATOLOGICNeutropenia96.953.898.666.796.431.4grade 3---29.8---23.7---19.3grade 4---24.0---42.5---12.1Leukopenia96.937.898.623.396.421.5Anemia96.98.498.65.596.94.5Neutropenic fever---7.1---14.6---5.8Thrombocytopenia96.02.698.62.796.01.7Neutropenic infection---1.8---0---2.2BODY AS WHOLEAsthenia70.219.564.411.969.113.9Pain30.73.126.93.622.92.2Fever42.21.732.43.643.50.4Infection22.2016.01.413.90.4METABOLIC NUTRITIONALBilirubin87.67.192.28.283.97.2DERMATOLOGICExfoliative dermatitis0.903.20.500Rash19.1026.50.914.30.4Alopecia 43.1---26.5---46.1---RESPIRATORYDyspnea27.66.316.00.522.02.2Cough26.71.318.3020.20.4Pneumonia6.22.71.41.03.61.3NEUROLOGICDizziness23.11.316.4021.11.8Somnolence12.41.84.61.89.41.3Confusion7.11.84.102.70CARDIOVASCULARVasodilatation9.30.95.009.00Hypotension5.81.32.30.55.81.7Thromboembolic events 9.3---11.4---5.4---a Severity of adverse events based on NCI CTC (version 1.0) Complete hair loss Grade c Includes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder. Table 6. Study 2: Percent (%) of Patients Experiencing Clinically Relevant Adverse Events in Combination Therapies Adverse EventStudy 2Irinotecan 5-FU/LV infusional days 1&2 every weeks N=1455-FU/LV infusion days 1&2 every weeks N=143Grades 1-4Grades 3&4Grades 1-4Grades 3&4Total Adverse Events10072.410039.2GASTROINTESTINALDiarrhealate72.414.444.86.3grade 3--10.3---4.2grade 4---4.1---2.1Cholinergic syndrome 28.31.40.70Nausea66.92.155.23.5Abdominal pain17.22.116.80.7Vomiting44.83.532.22.8Anorexia35.22.118.90.7Constipation30.30.725.21.4Mucositis40.04.128.72.8HEMATOLOGICNeutropenia82.546.247.913.4grade 3---36.4---12.7grade 4---9.8---0.7Leukopenia81.317.442.03.5Anemia97.22.190.92.1Neutropenic fever---3.4---0.7Thrombocytopenia32.6032.20Neutropenic infection---2.1---0BODY AS WHOLEAsthenia57.99.048.34.2Pain64.19.761.58.4Fever22.10.725.90.7Infection35.97.633.63.5METABOLIC AND NUTRITIONALBilirubin19.13.535.910.6DERMATOLOGICHand and foot syndrome10.30.712.60.7Cutaneous signs17.20.720.30Alopecia 56.6---16.8---RESPIRATORYDyspnea9.71.44.90CARDIOVASCULARHypotension3.41.40.70Thromboembolic events 11.7---5.6---a Severity of adverse events based on NCI CTC (version 1.0) Includes rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, abdominal cramping or diarrhea (occurring during or shortly after infusion of irinotecan) Complete hair loss Grade d Includes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder. Second-Line Single-Agent TherapyWeekly Dosage ScheduleIn three clinical studies evaluating the weekly dosage schedule, 304 patients with metastatic carcinoma of the colon or rectum that had recurred or progressed following 5-FU-based therapy were treated with irinotecan hydrochloride. Seventeen of the patients died within 30 days of the administration of irinotecan hydrochloride; in five cases (1.6%, 5/304), the deaths were potentially drug-related. One of the patients died of neutropenic sepsis without fever. Neutropenic fever occurred in nine (3.0%) other patients; these patients recovered with supportive care.One hundred nineteen (39.1%) of the 304 patients were hospitalized because of adverse events; 81 (26.6%) patients were hospitalized for events judged to be related to administration of irinotecan hydrochloride. The primary reasons for drug-related hospitalization were diarrhea, with or without nausea and/or vomiting (18.4%); neutropenia/leukopenia, with or without diarrhea and/or fever (8.2%); and nausea and/or vomiting (4.9%).The first dose of at least one cycle of irinotecan hydrochloride was reduced for 67% of patients who began the studies at the 125-mg/m starting dose. Within-cycle dose reductions were required for 32% of the cycles initiated at the 125-mg/m dose level. The most common reasons for dose reduction were late diarrhea, neutropenia, and leukopenia. Thirteen (4.3%) patients discontinued treatment with irinotecan hydrochloride because of adverse events. The adverse events in Table are based on the experience of the 304 patients enrolled in the three studies described in Clinical Studies (14.1). Table 7. Adverse Events Occurring in >10% of 304 Previously Treated Patients with Metastatic Carcinoma of the Colon or RectumaBody System Event% of Patients ReportingNCI Grades 1-4NCI Grades & 4GASTROINTESTINALDiarrhea (late)b7-9 stools/day (grade 3)>=10 stools/day (grade 4) NauseaVomitingAnorexiaDiarrhea (early)cConstipationFlatulenceStomatitisDyspepsia88--866755513012121031(16)(14)1712682010HEMATOLOGICLeukopeniaAnemiaNeutropenia500 to <1000/mm3 (grade 3)<500/mm3 (grade 4)636054--28726(15)(12)BODY AS WHOLEAstheniaAbdominal cramping/painFeverPainHeadacheBack painChillsMinor infection EdemaAbdominal enlargement76574524171414141010121612120010METABOLIC NUTRITIONAL Body weightDehydration Alkaline phosphatase SGOT301513101441DERMATOLOGICAlopeciaSweatingRash601613NA 01RESPIRATORYDyspnea CoughingRhinitis221716400NEUROLOGICInsomniaDizziness191500CARDIOVASCULARVasodilation (flushing)110a Severity of adverse events based on NCI CTC (version 1.0) Occurring >24 hours after administration of irinotecan hydrochloride Occurring <=24 hours after administration of irinotecan hydrochloride Primarily upper respiratory infections Not applicable; complete hair loss NCI grade Once-Every-3-Week Dosage ScheduleA total of 535 patients with metastatic colorectal cancer whose disease had recurred or progressed following prior 5-FU therapy participated in the two phase studies: 316 received irinotecan, 129 received 5-FU, and 90 received best supportive care. Eleven (3.5%) patients treated with irinotecan died within 30 days of treatment. In three cases (1%, 3/316), the deaths were potentially related to irinotecan treatment and were attributed to neutropenic infection, grade diarrhea, and asthenia, respectively. One (0.8%, 1/129) patient treated with 5-FU died within 30 days of treatment; this death was attributed to grade diarrhea.Hospitalizations due to serious adverse events occurred at least once in 60% (188/316) of patients who received irinotecan, 63% (57/90) who received best supportive care, and 39% (50/129) who received 5-FU-based therapy. Eight percent of patients treated with irinotecan and 7% treated with 5-FU-based therapy discontinued treatment due to adverse events.Of the 316 patients treated with irinotecan, the most clinically significant adverse events (all grades, 1-4) were diarrhea (84%), alopecia (72%), nausea (70%), vomiting (62%), cholinergic symptoms (47%), and neutropenia (30%). Table lists the grade and adverse events reported in the patients enrolled to all treatment arms of the two studies described in Clinical Studies (14.1).Table 8: Percent Of Patients Experiencing Grade & Adverse Events In Comparative Studies Of Once-Every-3-Week Irinotecan Therapy Adverse EventStudy 1Study 2IrinotecanN=189BSC N=90IrinotecanN=1275-FUN=129TOTAL Grade 3/4Adverse Events79676954GASTROINTESTINALDiarrheaVomitingNauseaAbdominal painConstipationAnorexiaMucositis22141414105268316871221411986211548645HEMATOLOGICLeukopenia/Neutropenia AnemiaHemorrhageThrombocytopeniaInfectionwithout grade 3/4neutropeniawith grade 3/4 neutropeniaFeverwithout grade 3/4neutropeniawith grade 3/4 neutropenia2275181220630301014614122423324002BODY AS WHOLEPainAsthenia1915221917131312METABOLIC AND NUTRITIONALHepatic 9796DERMATOLOGICHand and foot syndromeCutaneous signs 02000153RESPIRATORY e10857NEUROLOGIC 121394CARDIOVASCULARg9342OTHER 32281214a Severity of adverse events based on NCI CTC (version 1.0) BSC best supportive care Hepatic includes events such as ascites and jaundice Cutaneous signs include events such as rash Respiratory includes events such as dyspnea and cough Neurologic includes events such as somnolence Cardiovascular includes events such as dysrhythmias, ischemia, and mechanical cardiac dysfunction Other includes events such as accidental injury, hepatomegaly, syncope, vertigo, and weight loss The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as irinotecan hydrochloride than when these drugs were given on separate days (1.3%, 1/80 patients). The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as premedication for other chemotherapies.

CONTRAINDICATIONS SECTION.


4 CONTRAINDICATIONS. Irinotecan hydrochloride injection is contraindicated in patients with known hypersensitivity to the drug or its excipients.. Irinotecan hydrochloride injection is contraindicated in patients with known hypersensitivity to the drug or its excipients.. Hypersensitivity to irinotecan hydrochloride injection or its excipients (4).

DESCRIPTION SECTION.


11 DESCRIPTION. Irinotecan hydrochloride injection, USP is an antineoplastic agent of the topoisomerase inhibitor class.Irinotecan hydrochloride injection, USP is supplied as sterile, pale yellow, clear, aqueous solution. Each milliliter of solution contains 20 mg of irinotecan hydrochloride (on the basis of the trihydrate salt), 45 mg of sorbitol, NF, and 0.9 mg of lactic acid, USP. The pH of the solution has been adjusted to 3.5 (range, 3.0 to 3.8) with sodium hydroxide or hydrochloric acid. Irinotecan hydrochloride injection, USP is intended for dilution with 5% Dextrose Injection, USP (D5W), or 0.9% Sodium Chloride Injection, USP, prior to intravenous infusion. The preferred diluent is 5% Dextrose Injection, USP.Irinotecan hydrochloride is semisynthetic derivative of camptothecin, an alkaloid extract from plants such as Camptotheca acuminata or is chemically synthesized. The chemical name is [1, 4-bipiperidine]-1-carboxylic acid (4S) 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1 H-pyrano [3,4:6,7]indolizino[1,2- b]quinolin-9-yl ester hydrochloride trihydrate. Its empirical formula is 33H 38N 4O 6HCl.3H 2O and molecular weight is 677.18. It is slightly soluble in water and organic solvents. Its structural formula is as follows: structure.

DOSAGE & ADMINISTRATION SECTION.


2 DOSAGE AND ADMINISTRATION. Colorectal cancer single agent regimen 1: Irinotecan hydrochloride injection 125 mg/ 2 intravenous infusion over 90 minutes on days 1, 8, 15, 22 then 2-week rest. (2.2) Colorectal cancer single agent regimen 2: Irinotecan hydrochloride injection 350 mg/ 2 intravenous infusion over 90 minutes on day every weeks. (2.2) Colorectal cancer single agent regimen 1: Irinotecan hydrochloride injection 125 mg/ 2 intravenous infusion over 90 minutes on days 1, 8, 15, 22 then 2-week rest. (2.2) Colorectal cancer single agent regimen 2: Irinotecan hydrochloride injection 350 mg/ 2 intravenous infusion over 90 minutes on day every weeks. (2.2) 2.1 Colorectal Cancer Combination Regimens and 2. Administer irinotecan hydrochloride injection as 90-minute intravenous infusion followed by LV and 5-FU. The currently recommended regimens are shown in Table 1.A reduction in the starting dose by one dose level of irinotecan hydrochloride injection may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels. Dosing for patients with bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend dose in these patients.Table 1. Combination-Agent Dosage Regimens and Dose Modifications Regimen 16-wk cycle with bolus 5-FU/LV (next cycle begins on day 43)Irinotecan Hydrochloride InjectionLV5-FU125 mg/m intravenous infusion over 90 minutes, days 1,8,15,22 20 mg/m intravenous injection bolus, days 1,8,15,22 500 mg/m intravenous injection bolus, days 1,8,15,22 Starting Dose Modified Dose Levels (mg/m 2) Starting DoseDose Level -1Dose Level -2Irinotecan Hydrochloride InjectionLV5-FU12510075202020500400300Regimen 26-wk cycle with infusional5-FU/LV(next cycle begins on day 43)Irinotecan Hydrochloride InjectionLV5-FU Bolus5-FU Infusion 180 mg/m intravenous infusion over 90 minutes, days 1,15,29 200 mg/m intravenous infusion over hours, days 1,2,15,16,29,30 400 mg/m intravenous injection bolus, days 1,2,15,16,29,30 600 mg/m intravenous infusion over 22 hours, days 1,2,15,16,29,30 Starting Dose Modified Dose Levels (mg/m 2) Starting DoseDose Level -1Dose Level -2Irinotecan Hydrochloride InjectionLV1801501202002002005-FUBolus4003202405-FUInfusion 600480360a Dose reductions beyond Dose Level -2 by decrements of 20% may be warranted for patients continuing to experience toxicity. Provided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit. Infusion follows bolus administration. Dosing for patients with bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend dose in these patients [see Warnings and Precautions (5.10), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. Dose ModificationsBased on recommended dose levels described in Table 1, Combination Regimens of irinotecan hydrochloride injection and Dose Modifications, subsequent doses should be adjusted as suggested in Table 2, Recommended Dose Modifications for Combination Regimens. All dose modifications should be based on the worst preceding toxicity.Table 2. Recommended Dose Modifications for Irinotecan Hydrochloride Injection/5-Fluorouracil (5-FU)/Leucovorin (LV) Combination SchedulesPatients should return to pre-treatment bowel function without requiring antidiarrhea medications for at least 24 hours before the next chemotherapy administration. new cycle of therapy should not begin until the granulocyte count has recovered to >=1500/mm , and the platelet count has recovered to >=100,000/mm 3, and treatment-related diarrhea is fully resolved. Treatment should be delayed to weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after 2-week delay, consideration should be given to discontinuing therapy During Cycle of TherapyMaintain dose levelNeutropeniaMaintain dose level dose levelOmit dose until resolved to <= grade 2, then dose levelOmit dose until resolved to <= grade 2, then dose levelsOmit dose until resolved, then dose levelsDose modifications for leukopenia or thrombocytopenia during cycle of therapy and at the start of subsequent cycles of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.DiarrheaDelay dose until resolved to baseline, then give same doseOmit dose until resolved to baseline, then dose levelOmit dose until resolved to baseline, then dose levelOmit dose until resolved to baseline, then dose levelsOther nonhematologic toxicities Maintain dose levelOmit dose until resolved to <= grade 1, then dose levelOmit dose until resolved to <= grade 2, then dose levelOmit dose until resolved to <= grade 2, then dose levelsFor mucositis/stomatitis decrease only 5-FU, not Irinotecan Hydrochloride Injectiona National Cancer Institute Common Toxicity Criteria (version 1.0) Relative to the starting dose used in the previous cycle Pretreatment Excludes alopecia, anorexia, asthenia 2.2 Colorectal Single Agent Regimens and 2. Administer irinotecan hydrochloride injection as 90-minute intravenous infusion. The currently recommended regimens are shown in Table 3.A reduction in the starting dose by one dose level of irinotecan hydrochloride injection may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels. Dosing for patients with bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend dose in these patients.Table 3. Single-Agent Regimens of irinotecan hydrochloride injection and Dose ModificationsRegimen (weekly) 125 mg/m intravenous infusion over 90 minutes, days 1,8,15,22 then 2-week rest Starting Dose and Modified Dose Levels (mg/m 2) Starting Dose Dose Level -1 Dose Level -2 125 100 75Regimen (every weeks) 350 mg/m intravenous infusion over 90 minutes, once every weeks Starting Dose and Modified Dose Levels (mg/m 2) Starting Dose Dose Level -1 Dose Level -2 350 300 250a Subsequent doses may be adjusted as high as 150 mg/m or to as low as 50 mg/m in 25 to 50 mg/m decrements depending upon individual patient tolerance. Subsequent doses may be adjusted as low as 200 mg/m in 50 mg/m decrements depending upon individual patient tolerance. Provided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit.Dose ModificationsBased on recommended dose-levels described in Table 3, Single-Agent Regimens of irinotecan hydrochloride injection and Dose Modifications, subsequent doses should be adjusted as suggested in Table 4, Recommended Dose Modifications for Single-Agent Schedules. All dose modifications should be based on the worst preceding toxicity.Table 4: Recommended Dose Modifications For Single-Agent Schedules A new cycle of therapy should not begin until the granulocyte count has recovered to >=1500/mm 3, and the platelet count has recovered to >=100,000/mm 3, and treatment-related diarrhea is fully resolved. Treatment should be delayed to weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after 2-week delay, consideration should be given to discontinuing irinotecan hydrochloride injection. Worst ToxicityNCI Grade (Value)During Cycle of TherapyAt the Start of the Next Cycles of Therapy (After Adequate Recovery), Compared with the Starting Dose in the Previous Cycle WeeklyWeeklyOnce Every WeeksNo toxicityMaintain dose level 25 mg/m up to maximum dose of 150 mg/m Maintain dose levelNeutropenia1 (1500 to 1999/mm 3) Maintain dose levelMaintain dose levelMaintain dose level2 (1000 to 1499/mm 3) 25 mg/m Maintain dose levelMaintain dose level3 (500 to 999/mm 3) Omit dose until resolved to <= grade 2, then 25 mg/m 25 mg/m 50 mg/m 4 (<500/mm 3) Omit dose until resolved to <= grade 2, then 50 mg/m 50 mg/m 50 mg/m Neutropenic feverOmit dose until resolved, then 50 mg/m when resolved 50 mg/m 50 mg/m Other hematologictoxicitiesDose modifications for leukopenia, thrombocytopenia, and anemia during cycle of therapy and at the start of subsequent cycles of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.Diarrhea1 (2-3 stools/day pretx c) Maintain dose levelMaintain dose levelMaintain dose level2 (4-6 stools/day pretx) 25 mg/m Maintain dose levelMaintain dose level3 (7-9 stools/day pretx)Omit dose until resolved to <= grade 2, then 25 mg/m 25 mg/m 50 mg/m 4 (>=10 stools/day pretx)Omit dose until resolved to <= grade then 50 mg/m 50 mg/m 50 mg/m Other nonhematologic Toxicities1Maintain dose levelMaintain dose levelMaintain dose level2 25 mg/m 25 mg/m 50 mg/m 3Omit dose until resolved to <= grade 2, then 25 mg/m 25 mg/m 50 mg/m 4Omit dose until resolved to <= grade 2, then 50 mg/m 50 mg/m 50 mg/m a All dose modifications should be based on the worst preceding toxicity National Cancer Institute Common Toxicity Criteria (version 1.0) Pretreatment Excludes alopecia, anorexia, asthenia 2.3 Dosage in Patients with Reduced UGT1A1 Activity. When administered in combination with other agents, or as single-agent, reduction in the starting dose by at least one level of irinotecan hydrochloride injection should be considered for patients known to be homozygous for the UGT1A128 allele [see Dosage and Administration (2.1 and 2.2) and Warnings and Precautions (5.3)]. However, the precise dose reduction in this patient population is not known, and subsequent dose modifications should be considered based on individual patient tolerance to treatment (see Tables 1-4). 2.4 Premedication. It is recommended that patients receive premedication with antiemetic agents. In clinical studies of the weekly dosage schedule, the majority of patients received 10 mg of dexamethasone given in conjunction with another type of antiemetic agent, such as 5-HT blocker (e.g., ondansetron or granisetron). Antiemetic agents should be given on the day of treatment, starting at least 30 minutes before administration of irinotecan hydrochloride injection. Physicians should also consider providing patients with an antiemetic regimen (e.g., prochlorperazine) for subsequent use as needed. similar antiemetic regimen should be used with irinotecan hydrochloride injection in combination therapy. Prophylactic or therapeutic administration of atropine should be considered in patients experiencing cholinergic symptoms.. 2.5 Preparation of Infusion Solution. Inspect vial contents for particulate matter and discoloration and repeat inspection when drug product is withdrawn from vial into syringe.Irinotecan hydrochloride injection 20 mg/mL is intended for single use only and any unused portion should be discarded.Irinotecan hydrochloride injection must be diluted prior to infusion. Irinotecan hydrochloride injection should be diluted in 5% Dextrose Injection, USP, (preferred) or 0.9% Sodium Chloride Injection, USP, to final concentration range of 0.12 mg/mL to 2.8 mg/mL. Other drugs should not be added to the infusion solution.The solution is physically and chemically stable for up to 24 hours at room temperature and in ambient fluorescent lighting. Solutions diluted in 5% Dextrose Injection, USP, and stored at refrigerated temperatures (approximately to 8C, 36 to 46F), and protected from light are physically and chemically stable for 48 hours. Refrigeration of admixtures using 0.9% Sodium Chloride Injection, USP, is not recommended due to low and sporadic incidence of visible particulates. Freezing irinotecan hydrochloride injection and admixtures of irinotecan hydrochloride injection may result in precipitation of the drug and should be avoided.The irinotecan hydrochloride injection solution should be used immediately after reconstitution as it contains no antibacterial preservative. Because of possible microbial contamination during dilution, it is advisable to use the admixture prepared with 5% Dextrose Injection, USP, within 24 hours if refrigerated (2 to 8C, 36 to 46F). In the case of admixtures prepared with 5% Dextrose Injection, USP, or Sodium Chloride Injection, USP, the solutions should be used within hours if kept at room temperature. If reconstitution and dilution are performed under strict aseptic conditions (e.g., on Laminar Air Flow bench), irinotecan hydrochloride injection solution should be used (infusion completed) within 12 hours at room temperature or 24 hours if refrigerated (2 to 8C, 36 to 46F).. 2.6 Safe Handling. Care should be exercised in the handling and preparation of infusion solutions prepared from irinotecan hydrochloride injection. The use of gloves is recommended. If solution of irinotecan hydrochloride injection contacts the skin, wash the skin immediately and thoroughly with soap and water. If irinotecan hydrochloride injection contacts the mucous membranes, flush thoroughly with water. Several published guidelines for handling and disposal of anticancer agents are available.. 2.7 Extravasation. Care should be taken to avoid extravasation, and the infusion site should be monitored for signs of inflammation. Should extravasation occur, flushing the site with sterile water and applications of ice are recommended.

DOSAGE FORMS & STRENGTHS SECTION.


3 DOSAGE FORMS AND STRENGTHS. Irinotecan hydrochloride injection USP is available in two single-dose sizes:2 mL-fill vial containing 40 mg irinotecan hydrochloride injection, USP5 mL-fill vial containing 100 mg irinotecan hydrochloride injection, USP15 mL-fill vial containing 300 mg irinotecan hydrochloride injection, USP. mL-fill vial containing 40 mg irinotecan hydrochloride injection, USP. mL-fill vial containing 100 mg irinotecan hydrochloride injection, USP. 15 mL-fill vial containing 300 mg irinotecan hydrochloride injection, USP. Irinotecan hydrochloride injection, USP is available in two single-dose sizes:2 mL-fill vial containing 40 mg irinotecan hydrochloride injection, USP (3)5 mL-fill vial containing 100 mg irinotecan hydrochloride injection, USP (3)15 mL-fill vial containing 300 mg irinotecan hydrochloride injection, USP (3). mL-fill vial containing 40 mg irinotecan hydrochloride injection, USP (3). mL-fill vial containing 100 mg irinotecan hydrochloride injection, USP (3). 15 mL-fill vial containing 300 mg irinotecan hydrochloride injection, USP (3).

DRUG INTERACTIONS SECTION.


7 DRUG INTERACTIONS. Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with irinotecan hydrochloride injection. (7.2) Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with irinotecan hydrochloride injection (7.3) Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with irinotecan hydrochloride injection. (7.2) Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with irinotecan hydrochloride injection (7.3) 7.1 5-Fluorouracil (5-FU) and Leucovorin (LV). In phase clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. Although the max and AUC 0-24 of SN-38, the active metabolite, were reduced (by 14% and 8%, respectively) when irinotecan was followed by 5-FU and LV administration compared with when irinotecan was given alone, this sequence of administration was used in the combination trials and is recommended [see Dosage and Administration (2)]. Formal in vivo or in vitro drug interaction studies to evaluate the influence of irinotecan on the disposition of 5-FU and LV have not been conducted. 7.2 Strong CYP3A4 Inducers. Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. Johns wort. The appropriate starting dose for patients taking these or other strong inducers such as rifampin and rifabutin has not been defined. Consider substituting non-enzyme inducing therapies at least weeks prior to initiation of irinotecan hydrochloride therapy. Do not administer strong CYP3A4 inducers with irinotecan hydrochloride unless there are no therapeutic alternatives.. 7.3 Strong CYP3A4 or UGT1A1 Inhibitors. Irinotecan and its active metabolite, SN-38, are metabolized via the human cytochrome P450 3A4 isoenzyme (CYP3A4) and uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1), respectively, [see Clinical Pharmacology (12.3)]. Patients receiving concomitant ketoconazole, CYP3A4 and UGT1A1 inhibitor, have increased exposure to irinotecan and its active metabolite SN-38. Coadministration of irinotecan hydrochloride with other inhibitors of CYP3A4 (e.g., clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (e.g., atazanavir, gemfibrozil, indinavir) may increase systemic exposure to irinotecan or SN-38. Discontinue strong CYP3A4 inhibitors at least week prior to starting irinotecan hydrochloride therapy. Do not administer strong CYP3A4 or UGT1A1 inhibitors with irinotecan hydrochloride unless there are no therapeutic alternatives.

FEMALES & MALES OF REPRODUCTIVE POTENTIAL SECTION.


8.3 Females and Males of Reproductive Potential. Pregnancy TestingVerify the pregnancy status in female patients of reproductive potential prior to initiating irinotecan hydrochloride.ContraceptionIrinotecan hydrochloride can cause fetal harm when administered to pregnant woman.FemalesAdvise female patients of reproductive potential to use effective contraception during treatment and for months after the final dose of irinotecan hydrochloride see Use in Specific Populations (8.1) and Nonclinical Toxicology (13.1)]. MalesDue to the potential for genotoxicity, advise male patients with female partners of reproductive potential to use condoms during treatment and for months after the final dose of irinotecan hydrochloride see Nonclinical Toxicology (13.1)]. InfertilityFemalesBased on postmarketing reports, female fertility may be impaired by treatment with irinotecan hydrochloride. Menstrual dysfunction has been reported following irinotecan hydrochloride administrationMalesBased on findings from animal studies, male fertility may be impaired by treatment with irinotecan hydrochloride see Nonclinical Toxicology (13.1)].

GERIATRIC USE SECTION.


8.5 Geriatric Use. Patients greater than 65 years of age should be closely monitored because of greater risk of early and late diarrhea in this population [see Clinical Pharmacology (12.3) and Adverse Reactions (6.1)]. The starting dose of irinotecan hydrochloride in patients 70 years and older for the once- every-3-week-dosage schedule should be 300 mg/m [see Clinical Pharmacology (12.3) and Dosage and Administration (2)]. The frequency of grade and late diarrhea by age was significantly greater in patients >=65 years than in patients <65 years (40% [53/133] versus 23% [40/171]; p=0.002). In another study of 183 patients treated on the weekly schedule, the frequency of grade or late diarrhea in patients >=65 years of age was 28.6% [26/91] and in patients <65 years of age was 23.9% [22/92].

HEPATIC IMPAIRMENT SUBSECTION.


8.7 Hepatic Impairment. Irinotecan clearance is diminished in patients with hepatic impairment while exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function. The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations. Therefore, use caution when administering irinotecan hydrochloride to patients with hepatic impairment. The tolerability of irinotecan in patients with hepatic dysfunction (bilirubin greater than mg/dl) has not been assessed sufficiently, and no recommendations for dosing can be made [see Dosage and Administration (2.1), Warnings and Precautions (5.10) and Clinical Pharmacology (12.3)].

HOW SUPPLIED SECTION.


16 HOW SUPPLIED/STORAGE AND HANDLING. Irinotecan hydrochloride injection, USP is available in single-dose amber colored vials in the following package sizes:2 mL NDC 59923-714-025 mL NDC 59923-715-0515 mL NDC 59923-716-15Store at 20 to 25 oC (68 to 77 oF) [see USP Controlled Room Temperature]. Protect from light. Protect from freezing, Keep the vial in the carton until the time of use. Inspect the vial for damage and visible signs of leaks before removing from the carton. If damaged, incinerate the unopened package.

INDICATIONS & USAGE SECTION.


1 INDICATIONS AND USAGE. Irinotecan hydrochloride injection is indicated as component of first-line therapy in combination with 5--fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum.Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.. Irinotecan hydrochloride injection is indicated as component of first-line therapy in combination with 5--fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum.. Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.. Irinotecan hydrochloride injection is topoisomerase inhibitor indicated for:First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. (1)Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. (1). First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. (1). Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. (1).

LACTATION SECTION.


8.2 Lactation. Risk SummaryIrinotecan and its metabolites are present in human milk. There is no information regarding the effects of irinotecan on the breastfed infant, or on milk production. Because of the potential for serious adverse reactions from irinotecan hydrochloride in the breastfed child, advise lactating women not to breastfeed during treatment with irinotecan hydrochloride and for days after the final dose.

MECHANISM OF ACTION SECTION.


12.1 Mechanism of Action. Irinotecan is derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.

NONCLINICAL TOXICOLOGY SECTION.


13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term carcinogenicity studies with irinotecan were not conducted. Rats were, however, administered intravenous doses of mg/kg or 25 mg/kg irinotecan once per week for 13 weeks (in separate studies, the 25 mg/kg dose produced an irinotecan max and AUC that were about 7.0 times and 1.3 times the respective values in patients administered 125 mg/m weekly) and were then allowed to recover for 91 weeks. Under these conditions, there was significant linear trend with dose for the incidence of combined uterine horn endometrial stromal polyps and endometrial stromal sarcomas. Irinotecan was clastogenic both in vitro (chromosome aberrations in Chinese hamster ovary cells) and in vivo (micronucleus test in mice). Neither irinotecan nor its active metabolite SN-38 was mutagenic in the in vitro Ames assay. No significant adverse effects on fertility and general reproductive performance were observed after intravenous administration of irinotecan in doses of up to mg/kg/day to rats and rabbits; however, atrophy of male reproductive organs was observed after multiple daily irinotecan doses both in rodents at 20 mg/kg and in dogs at 0.4 mg/kg. In separate studies in rodents, this dose produced an irinotecan max and AUC about and times, respectively, of the corresponding values in patients administered 125 mg/m weekly. In dogs this dose produced an irinotecan max and AUC about one-half and 1/15th, respectively, of the corresponding values in patients administered 125 mg/m weekly.

OVERDOSAGE SECTION.


10 OVERDOSAGE. In U.S. phase trials, single doses of up to 345 mg/m of irinotecan were administered to patients with various cancers. Single doses of up to 750 mg/m of irinotecan have been given in non-U.S. trials. The adverse events in these patients were similar to those reported with the recommended dosage and regimen. There have been reports of overdosage at doses up to approximately twice the recommended therapeutic dose, which may be fatal. The most significant adverse reactions reported were severe neutropenia and severe diarrhea. There is no known antidote for overdosage of irinotecan hydrochloride. Maximum supportive care should be instituted to prevent dehydration due to diarrhea and to treat any infectious complications.

RECENT MAJOR CHANGES SECTION.


RECENT MAJOR CHANGES. Warnings and Precautions, Embryo-Fetal Toxicity (5.9) 01/2020.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.


NDC 59923-714-02Irinotecan HydrochlorideInjection, USP40 mg/2 mL(20 mg/mL)For Intravenous Use OnlyCaution: Cytotoxic Agent2 mL Single-Dose VialDiscard unused portionRx only Areva NDC 59923-714-02Irinotecan HydrochlorideInjection, USP40 mg/2 mL(20 mg/mL)For Intravenous Use OnlyCaution: Cytotoxic AgentOne mL Single-Dose VialDiscard unused portionRx only ArevaNDC 59923-715-05Irinotecan HydrochlorideInjection, USP100 mg/5 mL(20 mg/mL)For Intravenous Use OnlyCaution: Cytotoxic Agent5 mL Single-Dose VialDiscard unused portionRx only ArevaNDC 59923-715-05Irinotecan HydrochlorideInjection, USP100 mg/5 mL(20 mg/mL)For Intravenous Use OnlyCaution: Cytotoxic AgentOne mL Single-Dose VialDiscard unused portionRx only ArevaNDC 59923-716-15Irinotecan HydrochlorideInjection, USP300 mg/15 mL(20 mg/mL)For Intravenous Use OnlyCaution: Cytotoxic Agent15 mL Single-Dose VialDiscard unused portionRx only ArevaNDC 59923-716-15Irinotecan HydrochlorideInjection, USP300 mg/15 mL(20 mg/mL)For Intravenous Use OnlyCaution: Cytotoxic AgentOne 15 mL Single-Dose VialDiscard unused portionRx only Areva. unit label. carton label. unit label. carton. vial. carton.

PATIENT COUNSELING INFORMATION.


17 PATIENT COUNSELING INFORMATION. Patients and caregivers should be informed of gastrointestinal complications, such as nausea, vomiting, abdominal cramping, and diarrhea. Patients should have loperamide readily available to begin treatment for late diarrhea (generally occurring more than 24 hours after administration of irinotecan hydrochloride). Begin loperamide at the first episode of poorly formed or loose stools or the earliest onset of bowel movements more frequent than normal. One dosage regimen for loperamide is mg at the first onset of late diarrhea and then mg every hours until the patient is diarrhea-free for at least 12 hours. Loperamide is not recommended to be used for more than 48 consecutive hours at these doses, because of the risk of paralytic ileus. During the night, the patient may take mg of loperamide every hours. Patients should contact their physician if any of the following occur: diarrhea for the first time during treatment; black or bloody stools; symptoms of dehydration such as light headedness, dizziness, or faintness; inability to take fluids by mouth due to nausea or vomiting; or inability to get diarrhea under control within 24 hours.Patients should be warned about the potential for dizziness or visual disturbances which may occur within 24 hours following the administration of irinotecan hydrochloride injection.Explain the significance of routine blood cell counts. Instruct patients to monitor their temperature frequently and immediately report any occurrence of fever or infection.Embryo-Fetal Toxicity [see Warnings and Precautions (5.9), Use in Specific Populations (8.1 and 8.3), Clinical Pharmacology (12.1) and Nonclinical Toxicology (13.1)] Advise pregnant women and females of reproductive potential of the potential risk to fetus and to inform their healthcare provider of known or suspected pregnancy.Advise females of reproductive potential to use effective contraception during treatment with irinotecan hydrochloride and for months after the final dose.Advise male patients with female partners of reproductive potential to use condoms during treatment and for months after the final dose of irinotecan hydrochloride. LactationAdvise women not to breastfeed during treatment with irinotecan hydrochloride and for at least days after the final dose [see Use in Specific Populations (8.2)]. InfertilityAdvise females and males of reproductive potential that irinotecan hydrochloride may impair fertility [see Use in Specific Populations (8.3)]. Patients should be alerted to the possibility of alopecia.Contains sorbitol.Distributed by:Areva Pharmaceuticals, Inc.Georgetown, IN 47122Made in IndiaRevised: 04/2020. Patients and caregivers should be informed of gastrointestinal complications, such as nausea, vomiting, abdominal cramping, and diarrhea. Patients should have loperamide readily available to begin treatment for late diarrhea (generally occurring more than 24 hours after administration of irinotecan hydrochloride). Begin loperamide at the first episode of poorly formed or loose stools or the earliest onset of bowel movements more frequent than normal. One dosage regimen for loperamide is mg at the first onset of late diarrhea and then mg every hours until the patient is diarrhea-free for at least 12 hours. Loperamide is not recommended to be used for more than 48 consecutive hours at these doses, because of the risk of paralytic ileus. During the night, the patient may take mg of loperamide every hours. Patients should contact their physician if any of the following occur: diarrhea for the first time during treatment; black or bloody stools; symptoms of dehydration such as light headedness, dizziness, or faintness; inability to take fluids by mouth due to nausea or vomiting; or inability to get diarrhea under control within 24 hours.. Patients should be warned about the potential for dizziness or visual disturbances which may occur within 24 hours following the administration of irinotecan hydrochloride injection.. Explain the significance of routine blood cell counts. Instruct patients to monitor their temperature frequently and immediately report any occurrence of fever or infection.. Embryo-Fetal Toxicity [see Warnings and Precautions (5.9), Use in Specific Populations (8.1 and 8.3), Clinical Pharmacology (12.1) and Nonclinical Toxicology (13.1)] Advise pregnant women and females of reproductive potential of the potential risk to fetus and to inform their healthcare provider of known or suspected pregnancy.Advise females of reproductive potential to use effective contraception during treatment with irinotecan hydrochloride and for months after the final dose.Advise male patients with female partners of reproductive potential to use condoms during treatment and for months after the final dose of irinotecan hydrochloride. Advise pregnant women and females of reproductive potential of the potential risk to fetus and to inform their healthcare provider of known or suspected pregnancy.. Advise females of reproductive potential to use effective contraception during treatment with irinotecan hydrochloride and for months after the final dose.. Advise male patients with female partners of reproductive potential to use condoms during treatment and for months after the final dose of irinotecan hydrochloride.. Lactation. Advise women not to breastfeed during treatment with irinotecan hydrochloride and for at least days after the final dose [see Use in Specific Populations (8.2)]. Infertility. Advise females and males of reproductive potential that irinotecan hydrochloride may impair fertility [see Use in Specific Populations (8.3)]. Patients should be alerted to the possibility of alopecia.. Contains sorbitol.

PEDIATRIC USE SECTION.


8.4 Pediatric Use. The effectiveness of irinotecan in pediatric patients has not been established. Results from two open-label, single arm studies were evaluated. One hundred and seventy children with refractory solid tumors were enrolled in one phase trial in which 50 mg/ 2 of irinotecan was infused for consecutive days every weeks. Grade 3-4 neutropenia was experienced by 54 (31.8%) patients. Neutropenia was complicated by fever in 15 (8.8%) patients. Grade 3-4 diarrhea was observed in 35 (20.6%) patients. This adverse event profile was comparable to that observed in adults. In the second phase trial of 21 children with previously untreated rhabdomyosarcoma, 20 mg/m of irinotecan was infused for consecutive days on weeks 0, 1, and 4. This single agent therapy was followed by multimodal therapy. Accrual to the single agent irinotecan phase was halted due to the high rate (28.6%) of progressive disease and the early deaths (14%). The adverse event profile was different in this study from that observed in adults; the most significant grade or adverse events were dehydration experienced by patients (28.6%) associated with severe hypokalemia in patients (23.8%) and hyponatremia in patients (14.3%); in addition Grade 3-4 infection was reported in patients (23.8%) (across all courses of therapy and irrespective of causal relationship). Pharmacokinetic parameters for irinotecan and SN-38 were determined in pediatric solid-tumor trials at dose levels of 50 mg/m (60-min infusion, n=48) and 125 mg/m (90-min infusion, n=6). Irinotecan clearance (mean +- S.D.) was 17.3 +- 6.7 L/h/m for the 50 mg/m dose and 16.2 +- 4.6 L/h/m for the 125 mg/m dose, which is comparable to that in adults. Dose-normalized SN-38 AUC values were comparable between adults and children. Minimal accumulation of irinotecan and SN-38 was observed in children on daily dosing regimens [daily 5 every weeks or (daily 5) 2 weeks every weeks].

PHARMACODYNAMICS SECTION.


12.2 Pharmacodynamics. Irinotecan serves as water-soluble precursor of the lipophilic metabolite SN-38. SN-38 is formed from irinotecan by carboxylesterase-mediated cleavage of the carbamate bond between the camptothecin moiety and the dipiperidino side chain. SN-38 is approximately 1000 times as potent as irinotecan as an inhibitor of topoisomerase purified from human and rodent tumor cell lines. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold; however, the plasma area under the concentration versus time curve (AUC) values for SN-38 are 2% to 8% of irinotecan and SN-38 is 95% bound to plasma proteins compared to approximately 50% bound to plasma proteins for irinotecan [see Clinical Pharmacology (12.3)]. The precise contribution of SN-38 to the activity of irinotecan hydrochloride is thus unknown. Both irinotecan and SN-38 exist in an active lactone form and an inactive hydroxy acid anion form. pH-dependent equilibrium exists between the two forms such that an acid pH promotes the formation of the lactone, while more basic pH favors the hydroxy acid anion form. Administration of irinotecan has resulted in antitumor activity in mice bearing cancers of rodent origin and in human carcinoma xenografts of various histological types.

PHARMACOKINETICS SECTION.


12.3 Pharmacokinetics. After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in multiexponential manner, with mean terminal elimination half-life of about to 12 hours. The mean terminal elimination half-life of the active metabolite SN-38 is about 10 to 20 hours. The half-lives of the lactone (active) forms of irinotecan and SN-38 are similar to those of total irinotecan and SN-38, as the lactone and hydroxy acid forms are in equilibrium.Over the recommended dose range of 50 to 350 mg/m 2, the AUC of irinotecan increases linearly with dose; the AUC of SN-38 increases less than proportionally with dose. Maximum concentrations of the active metabolite SN-38 are generally seen within hour following the end of 90-minute infusion of irinotecan. Pharmacokinetic parameters for irinotecan and SN-38 following 90-minute infusion of irinotecan at dose levels of 125 and 340 mg/m determined in two clinical studies in patients with solid tumors are summarized in Table 9: Table 9. Summary of Mean (+-Standard Deviation) Irinotecan and SN-38 Pharmacokinetic Parameters in Patients with Solid TumorsDose(mg/m 2) IrinotecanSN-38C max (ng/mL)AUC 0-24 (ng.h/mL)t 1/2 (h)V (L/m 2) CL(L/h/m 2) max (ng/mL)AUC 0-24 (ng.h/mL)t 1/2 (h)125(N=64)1,660+-79710,200+-3,2705.8 +-0.7110+-48.513.3+-6.0126.3+-11.9229+-10810.4 +-3.1340(N=6)3,392+-87420,604+-6,02711.7 +-1.0234+-69.613.9+-4.056.0+-28.2474+-24521.0 +-4.3C max Maximum plasma concentration AUC 0-24 Area under the plasma concentration-time curve from time to 24 hours after the end of the 90-minute infusiont 1/2 Terminal elimination half-life z Volume of distribution of terminal elimination phase CL Total systemic clearancea Plasma specimens collected for 24 hours following the end of the 90-minute infusion Plasma specimens collected for 48 hours following the end of the 90-minute infusion. Because of the longer collection period, these values provide more accurate reflection of the terminal elimination half-lives of irinotecan and SN-38. DistributionIrinotecan exhibits moderate plasma protein binding (30% to 68% bound). SN-38 is highly bound to human plasma proteins (approximately 95% bound). The plasma protein to which irinotecan and SN-38 predominantly binds is albumin.MetabolismIrinotecan is subject to extensive metabolic conversion by various enzyme systems, including esterases to form the active metabolite SN-38, and UGT1A1 mediating glucuronidation of SN-38 to form the inactive glucuronide metabolite SN-38G. Irinotecan can also undergo CYP3A4- mediated oxidative metabolism to several inactive oxidation products, one of which can be hydrolyzed by carboxylesterase to release SN-38. In vitro studies indicate that irinotecan, SN-38 and another metabolite aminopentane carboxylic acid (APC), do not inhibit cytochrome P-450 isozymes. UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A128 polymorphism. Approximately 10% of the North American population is homozygous for the UGT1A128 allele (also referred to as UGT1A1 7/7 genotype). In prospective study, in which irinotecan was administered as single-agent (350 mg/m 2) on once-every-3-week schedule, patients with the UGT1A1 7/7 genotype had higher exposure to SN-38 than patients with the wild-type UGT1A1 allele (UGT1A1 6/6 genotype) [see Warnings and Precautions (5.3) and Dosage and Administration (2.3)]. SN-38 glucuronide had 1/50 to 1/100 the activity of SN-38 in cytotoxicity assays using two cell lines in vitro. ExcretionThe disposition of irinotecan has not been fully elucidated in humans. The urinary excretion of irinotecan is 11% to 20%; SN-38, <1%; and SN-38 glucuronide, 3%. The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over period of 48 hours following administration of irinotecan in two patients ranged from approximately 25% (100 mg/m 2) to 50% (300 mg/m 2). Effect of AgeThe pharmacokinetics of irinotecan administered using the weekly schedule was evaluated in study of 183 patients that was prospectively designed to investigate the effect of age on irinotecan toxicity. Results from this trial indicate that there are no differences in the pharmacokinetics of irinotecan, SN-38, and SN-38 glucuronide in patients <65 years of age compared with patients >=65 years of age. In study of 162 patients that was not prospectively designed to investigate the effect of age, small (less than 18%) but statistically significant differences in dose-normalized irinotecan pharmacokinetic parameters in patients <65 years of age compared to patients >=65 years of age were observed. Although dose-normalized AUC 0-24 for SN-38 in patients >=65 years of age was 11% higher than in patients <65 years of age, this difference was not statistically significant. No change in the starting dose is recommended for geriatric patients receiving the weekly dosage schedule of irinotecan [see Dosage and Administration (2)]. Effect of GenderThe pharmacokinetics of irinotecan do not appear to be influenced by gender.Effect of RaceThe influence of race on the pharmacokinetics of irinotecan has not been evaluated.Effect of Hepatic ImpairmentIrinotecan clearance is diminished in patients with hepatic impairment while exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function. The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations. However, the tolerability of irinotecan in patients with hepatic dysfunction (bilirubin greater than mg/dl) has not been assessed sufficiently, and no recommendations for dosing can be made [see Dosage and Administration (2.1), Warnings and Precautions (5.10) and Use in Specific Populations (8.7)]. Effect of Renal ImpairmentThe influence of renal impairment on the pharmacokinetics of irinotecan has not been evaluated. Therefore, caution should be undertaken in patients with impaired renal function. Irinotecan hydrochloride is not recommended for use in patients on dialysis [see Use in Specific Populations (8.6)]. Drug InteractionsDexamethasone, moderate CYP3A4 inducer, does not appear to alter the pharmacokinetics of irinotecan.

PREGNANCY SECTION.


8.1 Pregnancy. Risk SummaryBased on findings from animal studies and its mechanism of action, irinotecan hydrochloride can cause fetal harm when administered to pregnant woman see Clinical Pharmacology (12.1)]. Available postmarketing and published data reporting the use of irinotecan hydrochloride in pregnant women, are insufficient and confounded by the concomitant use of other cytotoxic drugs, to evaluate for any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal studies, intravenous administration of irinotecan to rats and rabbits during the period of organogenesis resulted in embryofetal mortality and teratogenicity in pregnant animals at exposures lower than the human exposure based on AUC at the clinical dose of 125 mg/m ( see Data). Advise pregnant women of the potential risk to fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and 15 to 20%, respectively.DataAnimal DataRadioactivity related to 14C-irinotecan crosses the placenta of rats following intravenous administration. Intravenous administration of irinotecan to rats at dose of mg/kg/day (approximately 0.2 times the clinical exposure (AUC) at the 125 mg/m dose based on exposure data from separate rat study) during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses; at doses >= 1.2 mg/kg/day (approximately 0.03 times the clinical exposure (AUC) at the 125 mg/m dose based on exposure data from separate rat study) there were increases in variety of external, visceral, and skeletal abnormalities. Administration of irinotecan to pregnant rabbits at dose of mg/kg (approximately half of the clinical dose of 125 mg/m based on BSA) resulted in similar findings to those in rats, with increased post-implantation loss, decreased live fetuses, and increased external, visceral, and skeletal abnormalities. Irinotecan administered to rat dams for the period following organogenesis through weaning at doses of mg/kg/day caused decreased learning ability and decreased female body weights in the offspring.

REFERENCES SECTION.


15 REFERENCES. NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otmvi/otmvi2.htmlAmerican Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am Health-Syst Pharm. 2006; 63:1172-1193. Polovich, M., White, J. M., Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.. NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.. OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otmvi/otmvi2.html. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am Health-Syst Pharm. 2006; 63:1172-1193. Polovich, M., White, J. M., Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.

RENAL IMPAIRMENT SUBSECTION.


8.6 Renal Impairment. The influence of renal impairment on the pharmacokinetics of irinotecan has not been evaluated. Therefore, use caution in patients with impaired renal function. irinotecan hydrochloride is not recommended for use in patients on dialysis.

SPL UNCLASSIFIED SECTION.


2.1 Colorectal Cancer Combination Regimens and 2. Administer irinotecan hydrochloride injection as 90-minute intravenous infusion followed by LV and 5-FU. The currently recommended regimens are shown in Table 1.A reduction in the starting dose by one dose level of irinotecan hydrochloride injection may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels. Dosing for patients with bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend dose in these patients.Table 1. Combination-Agent Dosage Regimens and Dose Modifications Regimen 16-wk cycle with bolus 5-FU/LV (next cycle begins on day 43)Irinotecan Hydrochloride InjectionLV5-FU125 mg/m intravenous infusion over 90 minutes, days 1,8,15,22 20 mg/m intravenous injection bolus, days 1,8,15,22 500 mg/m intravenous injection bolus, days 1,8,15,22 Starting Dose Modified Dose Levels (mg/m 2) Starting DoseDose Level -1Dose Level -2Irinotecan Hydrochloride InjectionLV5-FU12510075202020500400300Regimen 26-wk cycle with infusional5-FU/LV(next cycle begins on day 43)Irinotecan Hydrochloride InjectionLV5-FU Bolus5-FU Infusion 180 mg/m intravenous infusion over 90 minutes, days 1,15,29 200 mg/m intravenous infusion over hours, days 1,2,15,16,29,30 400 mg/m intravenous injection bolus, days 1,2,15,16,29,30 600 mg/m intravenous infusion over 22 hours, days 1,2,15,16,29,30 Starting Dose Modified Dose Levels (mg/m 2) Starting DoseDose Level -1Dose Level -2Irinotecan Hydrochloride InjectionLV1801501202002002005-FUBolus4003202405-FUInfusion 600480360a Dose reductions beyond Dose Level -2 by decrements of 20% may be warranted for patients continuing to experience toxicity. Provided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit. Infusion follows bolus administration. Dosing for patients with bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend dose in these patients [see Warnings and Precautions (5.10), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. Dose ModificationsBased on recommended dose levels described in Table 1, Combination Regimens of irinotecan hydrochloride injection and Dose Modifications, subsequent doses should be adjusted as suggested in Table 2, Recommended Dose Modifications for Combination Regimens. All dose modifications should be based on the worst preceding toxicity.Table 2. Recommended Dose Modifications for Irinotecan Hydrochloride Injection/5-Fluorouracil (5-FU)/Leucovorin (LV) Combination SchedulesPatients should return to pre-treatment bowel function without requiring antidiarrhea medications for at least 24 hours before the next chemotherapy administration. new cycle of therapy should not begin until the granulocyte count has recovered to >=1500/mm , and the platelet count has recovered to >=100,000/mm 3, and treatment-related diarrhea is fully resolved. Treatment should be delayed to weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after 2-week delay, consideration should be given to discontinuing therapy During Cycle of TherapyMaintain dose levelNeutropeniaMaintain dose level dose levelOmit dose until resolved to <= grade 2, then dose levelOmit dose until resolved to <= grade 2, then dose levelsOmit dose until resolved, then dose levelsDose modifications for leukopenia or thrombocytopenia during cycle of therapy and at the start of subsequent cycles of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.DiarrheaDelay dose until resolved to baseline, then give same doseOmit dose until resolved to baseline, then dose levelOmit dose until resolved to baseline, then dose levelOmit dose until resolved to baseline, then dose levelsOther nonhematologic toxicities Maintain dose levelOmit dose until resolved to <= grade 1, then dose levelOmit dose until resolved to <= grade 2, then dose levelOmit dose until resolved to <= grade 2, then dose levelsFor mucositis/stomatitis decrease only 5-FU, not Irinotecan Hydrochloride Injectiona National Cancer Institute Common Toxicity Criteria (version 1.0) Relative to the starting dose used in the previous cycle Pretreatment Excludes alopecia, anorexia, asthenia.

USE IN SPECIFIC POPULATIONS SECTION.


8 USE IN SPECIFIC POPULATIONS. Lactation: Advise not to breastfeed. (8.2) Geriatric Use: Closely monitor patients greater than 65 years of age because of greater risk of early and late diarrhea in this population. (8.5) Patients with Renal Impairment: Use caution and do not use in patients on dialysis. (8.6) Patients with Hepatic Impairment: Use caution. (2.1, 5.10, 8.7, 12.3) See 17 for PATIENT COUNSELING INFORMATION.Revised: 11/2020. Lactation: Advise not to breastfeed. (8.2) Geriatric Use: Closely monitor patients greater than 65 years of age because of greater risk of early and late diarrhea in this population. (8.5) Patients with Renal Impairment: Use caution and do not use in patients on dialysis. (8.6) Patients with Hepatic Impairment: Use caution. (2.1, 5.10, 8.7, 12.3) 8.1 Pregnancy. Risk SummaryBased on findings from animal studies and its mechanism of action, irinotecan hydrochloride can cause fetal harm when administered to pregnant woman see Clinical Pharmacology (12.1)]. Available postmarketing and published data reporting the use of irinotecan hydrochloride in pregnant women, are insufficient and confounded by the concomitant use of other cytotoxic drugs, to evaluate for any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal studies, intravenous administration of irinotecan to rats and rabbits during the period of organogenesis resulted in embryofetal mortality and teratogenicity in pregnant animals at exposures lower than the human exposure based on AUC at the clinical dose of 125 mg/m ( see Data). Advise pregnant women of the potential risk to fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and 15 to 20%, respectively.DataAnimal DataRadioactivity related to 14C-irinotecan crosses the placenta of rats following intravenous administration. Intravenous administration of irinotecan to rats at dose of mg/kg/day (approximately 0.2 times the clinical exposure (AUC) at the 125 mg/m dose based on exposure data from separate rat study) during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses; at doses >= 1.2 mg/kg/day (approximately 0.03 times the clinical exposure (AUC) at the 125 mg/m dose based on exposure data from separate rat study) there were increases in variety of external, visceral, and skeletal abnormalities. Administration of irinotecan to pregnant rabbits at dose of mg/kg (approximately half of the clinical dose of 125 mg/m based on BSA) resulted in similar findings to those in rats, with increased post-implantation loss, decreased live fetuses, and increased external, visceral, and skeletal abnormalities. Irinotecan administered to rat dams for the period following organogenesis through weaning at doses of mg/kg/day caused decreased learning ability and decreased female body weights in the offspring.. 8.2 Lactation. Risk SummaryIrinotecan and its metabolites are present in human milk. There is no information regarding the effects of irinotecan on the breastfed infant, or on milk production. Because of the potential for serious adverse reactions from irinotecan hydrochloride in the breastfed child, advise lactating women not to breastfeed during treatment with irinotecan hydrochloride and for days after the final dose.. 8.3 Females and Males of Reproductive Potential. Pregnancy TestingVerify the pregnancy status in female patients of reproductive potential prior to initiating irinotecan hydrochloride.ContraceptionIrinotecan hydrochloride can cause fetal harm when administered to pregnant woman.FemalesAdvise female patients of reproductive potential to use effective contraception during treatment and for months after the final dose of irinotecan hydrochloride see Use in Specific Populations (8.1) and Nonclinical Toxicology (13.1)]. MalesDue to the potential for genotoxicity, advise male patients with female partners of reproductive potential to use condoms during treatment and for months after the final dose of irinotecan hydrochloride see Nonclinical Toxicology (13.1)]. InfertilityFemalesBased on postmarketing reports, female fertility may be impaired by treatment with irinotecan hydrochloride. Menstrual dysfunction has been reported following irinotecan hydrochloride administrationMalesBased on findings from animal studies, male fertility may be impaired by treatment with irinotecan hydrochloride see Nonclinical Toxicology (13.1)]. 8.4 Pediatric Use. The effectiveness of irinotecan in pediatric patients has not been established. Results from two open-label, single arm studies were evaluated. One hundred and seventy children with refractory solid tumors were enrolled in one phase trial in which 50 mg/ 2 of irinotecan was infused for consecutive days every weeks. Grade 3-4 neutropenia was experienced by 54 (31.8%) patients. Neutropenia was complicated by fever in 15 (8.8%) patients. Grade 3-4 diarrhea was observed in 35 (20.6%) patients. This adverse event profile was comparable to that observed in adults. In the second phase trial of 21 children with previously untreated rhabdomyosarcoma, 20 mg/m of irinotecan was infused for consecutive days on weeks 0, 1, and 4. This single agent therapy was followed by multimodal therapy. Accrual to the single agent irinotecan phase was halted due to the high rate (28.6%) of progressive disease and the early deaths (14%). The adverse event profile was different in this study from that observed in adults; the most significant grade or adverse events were dehydration experienced by patients (28.6%) associated with severe hypokalemia in patients (23.8%) and hyponatremia in patients (14.3%); in addition Grade 3-4 infection was reported in patients (23.8%) (across all courses of therapy and irrespective of causal relationship). Pharmacokinetic parameters for irinotecan and SN-38 were determined in pediatric solid-tumor trials at dose levels of 50 mg/m (60-min infusion, n=48) and 125 mg/m (90-min infusion, n=6). Irinotecan clearance (mean +- S.D.) was 17.3 +- 6.7 L/h/m for the 50 mg/m dose and 16.2 +- 4.6 L/h/m for the 125 mg/m dose, which is comparable to that in adults. Dose-normalized SN-38 AUC values were comparable between adults and children. Minimal accumulation of irinotecan and SN-38 was observed in children on daily dosing regimens [daily 5 every weeks or (daily 5) 2 weeks every weeks]. 8.5 Geriatric Use. Patients greater than 65 years of age should be closely monitored because of greater risk of early and late diarrhea in this population [see Clinical Pharmacology (12.3) and Adverse Reactions (6.1)]. The starting dose of irinotecan hydrochloride in patients 70 years and older for the once- every-3-week-dosage schedule should be 300 mg/m [see Clinical Pharmacology (12.3) and Dosage and Administration (2)]. The frequency of grade and late diarrhea by age was significantly greater in patients >=65 years than in patients <65 years (40% [53/133] versus 23% [40/171]; p=0.002). In another study of 183 patients treated on the weekly schedule, the frequency of grade or late diarrhea in patients >=65 years of age was 28.6% [26/91] and in patients <65 years of age was 23.9% [22/92].. 8.6 Renal Impairment. The influence of renal impairment on the pharmacokinetics of irinotecan has not been evaluated. Therefore, use caution in patients with impaired renal function. irinotecan hydrochloride is not recommended for use in patients on dialysis.. 8.7 Hepatic Impairment. Irinotecan clearance is diminished in patients with hepatic impairment while exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function. The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations. Therefore, use caution when administering irinotecan hydrochloride to patients with hepatic impairment. The tolerability of irinotecan in patients with hepatic dysfunction (bilirubin greater than mg/dl) has not been assessed sufficiently, and no recommendations for dosing can be made [see Dosage and Administration (2.1), Warnings and Precautions (5.10) and Clinical Pharmacology (12.3)].

WARNINGS AND PRECAUTIONS SECTION.


5 WARNINGS AND PRECAUTIONS. Diarrhea and Cholinergic Reactions: Early diarrhea (occurring during or shortly after infusion of irinotecan hydrochloride injection) is usually transient and may be accompanied by cholinergic symptoms. Consider prophylactic or therapeutic administration of 0.25 mg to mg of intravenous or subcutaneous atropine (unless clinically contraindicated). Late diarrhea (generally occurring more than 24 hours after administration of irinotecan hydrochloride injection) can occur. Monitor and replace fluid and electrolytes. Treat with loperamide. Use antibiotic support for ileus and fever. Interrupt irinotecan hydrochloride injection and reduce subsequent doses if severe diarrhea occurs. (5.1)Myelosuppression: Manage promptly with antibiotic support. Interrupt irinotecan hydrochloride injection and reduce subsequent doses if necessary. (5.2) Patients with Reduced UGT1A1 Activity: Individuals who are homozygous for the UGT1A128 allele are at increased risk for neutropenia following initiation of irinotecan hydrochloride injection treatment. (5.3) Hypersensitivity: Hypersensitivity reactions including severe anaphylactic or anaphylactoid reactions have been observed. Discontinue irinotecan hydrochloride injection if this occurs. (5.4) Renal Impairment/Renal Failure: Rare cases of renal impairment and acute renal failure have been identified, usually in patients who became volume depleted from severe vomiting and/or diarrhea. (5.5) Pulmonary Toxicity: Interstitial Pulmonary Disease (IPD)-like events, including fatalities, have occurred. Interrupt for new or progressive dysnpnea, cough, and fever pending evaluation. If IPD diagnosed, discontinue and institute appropriate treatment as needed. (5.6) Toxicity of the Day Regimen: Irinotecan hydrochloride injection should not be used in combination with regimen of 5-FU/LV administered for 4-5 consecutive days every weeks outside of clinical study. (5.7) Embryo-Fetal Toxicity: Irinotecan hydrochloride injection can cause fetal harm. Advise females of reproductive potential of the potential risk to fetus and to use effective contraception. Advise male patients with female partners of reproductive potential to use condoms. (5.9, 8.1, 8.3) Patients with Hepatic Impairment: In clinical trials, irinotecan hydrochloride injection has not been administered to patients with serum bilirubin 2.0 mg/dL, or transaminases 3 times ULN if no liver metastases, or transaminases 5 times ULN if liver metastases. With the weekly dosage schedule, patients with total bilirubin levels 1.0-2.0 mg/dL had greater likelihood of grade 3-4 neutropenia. (5.10) Diarrhea and Cholinergic Reactions: Early diarrhea (occurring during or shortly after infusion of irinotecan hydrochloride injection) is usually transient and may be accompanied by cholinergic symptoms. Consider prophylactic or therapeutic administration of 0.25 mg to mg of intravenous or subcutaneous atropine (unless clinically contraindicated). Late diarrhea (generally occurring more than 24 hours after administration of irinotecan hydrochloride injection) can occur. Monitor and replace fluid and electrolytes. Treat with loperamide. Use antibiotic support for ileus and fever. Myelosuppression: Manage promptly with antibiotic support. Interrupt irinotecan hydrochloride injection and reduce subsequent doses if necessary. (5.2) Patients with Reduced UGT1A1 Activity: Individuals who are homozygous for the UGT1A128 allele are at increased risk for neutropenia following initiation of irinotecan hydrochloride injection treatment. (5.3) Hypersensitivity: Hypersensitivity reactions including severe anaphylactic or anaphylactoid reactions have been observed. Discontinue irinotecan hydrochloride injection if this occurs. (5.4) Renal Impairment/Renal Failure: Rare cases of renal impairment and acute renal failure have been identified, usually in patients who became volume depleted from severe vomiting and/or diarrhea. (5.5) Pulmonary Toxicity: Interstitial Pulmonary Disease (IPD)-like events, including fatalities, have occurred. Interrupt for new or progressive dysnpnea, cough, and fever pending evaluation. If IPD diagnosed, discontinue and institute appropriate treatment as needed. (5.6) Toxicity of the Day Regimen: Irinotecan hydrochloride injection should not be used in combination with regimen of 5-FU/LV administered for 4-5 consecutive days every weeks outside of clinical study. (5.7) Embryo-Fetal Toxicity: Irinotecan hydrochloride injection can cause fetal harm. Advise females of reproductive potential of the potential risk to fetus and to use effective contraception. Advise male patients with female partners of reproductive potential to use condoms. (5.9, 8.1, 8.3) Patients with Hepatic Impairment: In clinical trials, irinotecan hydrochloride injection has not been administered to patients with serum bilirubin 2.0 mg/dL, or transaminases 3 times ULN if no liver metastases, or transaminases 5 times ULN if liver metastases. With the weekly dosage schedule, patients with total bilirubin levels 1.0-2.0 mg/dL had greater likelihood of grade 3-4 neutropenia. (5.10) 5.1 Diarrhea and Cholinergic Reactions. Early diarrhea (occurring during or shortly after infusion of irinotecan hydrochloride) is usually transient and infrequently severe. It may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Bradycardia may also occur. Early diarrhea and other cholinergic symptoms may be prevented or treated. Consider prophylactic or therapeutic administration of 0.25 mg to mg of intravenous or subcutaneous atropine (unless clinically contraindicated). These symptoms are expected to occur more frequently with higher irinotecan doses.Late diarrhea (generally occurring more than 24 hours after administration of irinotecan hydrochloride) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Grade 3-4 late diarrhea occurred in 23-31% of patients receiving weekly dosing. In the clinical studies, the median time to the onset of late diarrhea was days with 3-week dosing and 11 days with weekly dosing. Late diarrhea can be complicated by colitis, ulceration, bleeding, ileus, obstruction, and infection. Cases of megacolon and intestinal perforation have been reported. Patients should have loperamide readily available to begin treatment for late diarrhea. Begin loperamide at the first episode of poorly formed or loose stools or the earliest onset of bowel movements more frequent than normal. One dosage regimen for loperamide is mg at the first onset of late diarrhea and then mg every hours until the patient is diarrhea-free for at least 12 hours. Loperamide is not recommended to be used for more than 48 consecutive hours at these doses, because of the risk of paralytic ileus. During the night, the patient may take mg of loperamide every hours. Monitor and replace fluid and electrolytes. Use antibiotic support for ileus, fever, or severe neutropenia. Subsequent weekly chemotherapy treatments should be delayed in patients until return of pretreatment bowel function for at least 24 hours without anti-diarrhea medication. Patients must not be treated with irinotecan hydrochloride until resolution of the bowel obstruction. If grade 2, 3, or late diarrhea recurs, subsequent doses of irinotecan hydrochloride should be decreased [see Dosage and Administration (2)]. Avoid diuretics or laxatives in patients with diarrhea.. 5.2 Myelosuppression. Irinotecan hydrochloride can cause severe myelosuppression. Bacterial, viral, and fungal infections have occurred in patients treated with irinotecan hydrochloride.Deaths due to sepsis following severe neutropenia have been reported in patients treated with irinotecan hydrochloride. In the clinical studies evaluating the weekly dosage schedule, neutropenic fever (concurrent NCI grade neutropenia and fever of grade or greater) occurred in 3% of the patients; 6% of patients received G-CSF for the treatment of neutropenia. Manage febrile neutropenia promptly with antibiotic support [see Warnings and Precautions (5.2)]. Hold irinotecan hydrochloride if neutropenic fever occurs or if the absolute neutrophil count drops <1000/mm 3. After recovery to an absolute neutrophil count >=1000/mm 3, subsequent doses of irinotecan hydrochloride should be reduced [see Dosage and Administration (2)]. When evaluated in the trials of weekly administration, the frequency of grade and neutropenia was higher in patients who received previous pelvic/abdominal irradiation than in those who had not received such irradiation (48% [13/27] versus 24% [67/277]; p=0.04). Patients who have previously received pelvic/abdominal irradiation are at increased risk of severe myelosuppression following the administration ofiIrinotecan hydrochloride. Based on sparse available data, the concurrent administration of irinotecan hydrochloride with irradiation is not recommended.Patients with baseline serum total bilirubin levels of 1.0 mg/dL or more also had greater likelihood of experiencing first-cycle grade or neutropenia than those with bilirubin levels that were less than 1.0 mg/dL (50% [19/38] versus 18% [47/266]; p<0.001). Patients with deficient glucuronidation of bilirubin, such as those with Gilberts syndrome, may be at greater risk of myelosuppression when receiving therapy with irinotecan hydrochloride.. 5.3 Patients With Reduced UGT1A1 Activity. Individuals who are homozygous for the UGT1A128 allele (UGT1A1 7/7 genotype) are at increased risk for neutropenia following initiation of irinotecan hydrochloride treatment.In study of 66 patients who received single-agent irinotecan hydrochloride (350 mg/m once-every-3-weeks), the incidence of grade neutropenia in patients homozygous for the UGT1A128 allele was 50%, and in patients heterozygous for this allele (UGT1A1 6/7 genotype) the incidence was 12.5%. No grade neutropenia was observed in patients homozygous for the wild-type allele (UGT1A1 6/6 genotype). In prospective study (n=250) to investigate the role of UGT1A128 polymorphism in the development of toxicity in patients treated with irinotecan hydrochloride injection (180 mg/m 2) in combination with infusional 5-FU/LV, the incidence of grade neutropenia in patients homozygous for the UGT1A128 allele was 4.5%, and in patients heterozygous for this allele the incidence was 5.3%. Grade neutropenia was observed in 1.8% of patients homozygous for the wild-type allele. In another study in which 109 patients were treated with irinotecan hydrochloride injection (100 to 125 mg/m ) in combination with bolus 5-FU/LV, the incidence of grade neutropenia in patients homozygous for the UGT1A128 allele was 18.2%, and in patients heterozygous for this allele the incidence was 11.1%. Grade neutropenia was observed in 6.8% of patients homozygous for the wild-type allele. When administered in combination with other agents or as single-agent, reduction in the starting dose by at least one level of irinotecan hydrochloride should be considered for patients known to be homozygous for the UGT1A128 allele. However, the precise dose reduction in this patient population is not known and subsequent dose modifications should be considered based on individual patient tolerance to treatment [see Dosage and Administration (2)]. UGT1A1 TestingA laboratory test is available to determine the UGT1A1 status of patients. Testing can detect the UGT1A1 6/6, 6/7 and 7/7 genotypes.. 5.4 Hypersensitivity. Hypersensitivity reactions including severe anaphylactic or anaphylactoid reactions have been observed. Discontinue irinotecan hydrochloride if anaphylactic reaction occurs.. 5.5 Renal Impairment/Renal Failure. Renal impairment and acute renal failure have been identified, usually in patients who became volume depleted from severe vomiting and/or diarrhea.. 5.6 Pulmonary Toxicity. Interstitial Pulmonary Disease (IPD)-like events, including fatalities, have occurred in patients receiving irinotecan (in combination and as monotherapy). Risk factors include pre-existing lung disease, use of pneumotoxic drugs, radiation therapy, and colony stimulating factors. Patients with risk factors should be closely monitored for respiratory symptoms before and during Irinotecan hydrochloride therapy. In Japanese studies, reticulonodular pattern on chest x-ray was observed in small percentage of patients. New or progressive, dyspnea, cough, and fever should prompt interruption of chemotherapy, pending diagnostic evaluation. If IPD is diagnosed, irinotecan hydrochloride and other chemotherapy should be discontinued and appropriate treatment instituted as needed [see Adverse Reactions (6.1)]. 5.7 Toxicity of the Day Regimen. Outside of well-designed clinical study, irinotecan hydrochloride injection should not be used in combination with regimen of 5-FU/LV administered for 4-5 consecutive days every weeks because of reports of increased toxicity, including toxic deaths. Irinotecan hydrochloride injection should be used as recommended in Table [see Dosage and Administration (2)]. 5.8 Increased Toxicity in Patients with Performance Status 2. In patients receiving either irinotecan/5-FU/LV or 5-FU/LV in the clinical trials, higher rates of hospitalization, neutropenic fever, thromboembolism, first-cycle treatment discontinuation, and early deaths were observed in patients with baseline performance status of than in patients with baseline performance status of or 1.. 5.9 Embryo-Fetal Toxicity. Based on its mechanism of action and findings in animals, irinotecan hydrochloride can cause fetal harm when administered to pregnant woman. In animal studies, intravenous administration of irinotecan during the period of organogenesis resulted in embryofetal mortality and teratogenicity in pregnant animals at exposures lower than the human exposure based on area under the curve (AUC) at the clinical dose of 125 mg/m 2. Advise pregnant women of the potential risk to fetus. Advise female patients of reproductive potential to avoid becoming pregnant and to use highly effective contraception during treatment with irinotecan hydrochloride injection and for months after the final dose. Advise male patients with female partners of reproductive potential to use condoms during treatment and for months after the final dose of irinotecan hydrochloride injection see Use in Specific Populations (8.1), (8.3) and Nonclinical Toxicology (13.1)]. 5.10 Patients with Hepatic Impairment. The use of irinotecan hydrochloride in patients with significant hepatic impairment has not been established. In clinical trials of either dosing schedule, irinotecan was not administered to patients with serum bilirubin >2.0 mg/dL, or transaminase >3 times the upper limit of normal if no liver metastasis, or transaminase >5 times the upper limit of normal with liver metastasis. In clinical trials of the weekly dosage schedule, patients with modestly elevated baseline serum total bilirubin levels (1.0 to 2.0 mg/dL) had significantly greater likelihood of experiencing first-cycle, grade or neutropenia than those with bilirubin levels that were less than 1.0 mg/dL (50% [19/38] versus 18% [47/226]; p<0.001) [see Dosage and Administration (2), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].